Table 1 Clinical and demographic characteristics of participants
HNCH | FSD | BGI | PUSH | ALL | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Cancer | Non-Cancer | Cancer | Non-Cancer | Cancer | Non-Cancer | Cancer | Non-Cancer | Cancer | Non-Cancer | |
n = 869 | n = 555 | n = 18 | n = 110 | n = 34 | n = 416 | n = 149 | n = 3589 | n = 3029 | n = 12093 | |
Platform | Roche cobas e601/e602 | Roche cobas e601 | GBI ELISA | Abbott I2000 | ||||||
Sample type | Serum | Plasma | Plasma | Serum | ||||||
Age | ||||||||||
Mean (SD) | 62.5 (11.8) | 50.9 (11.6) | 61.3 (17.5) | 47.5 (14.0) | 33.8 (6.0) | 32.3 (5.2) | 59.1 (11.5) | 49.4 (11.6) | 60.2 (13.6) | 50.8 (15.5) |
≤55, n (%) | 220 (25.3%) | 392 (70.6%) | 8 (44.4%) | 76 (69.1%) | 34 (100.0%) | 416 (100.0%) | 57 (38.3%) | 2680 (74.7%) | 1030 (34.0%) | 7600 (62.8%) |
å 55, n (%) | 649 (74.7%) | 163 (29.4%) | 10 (55.6%) | 34 (30.9%) | 0 (0.0%) | 0 (0.0%) | 92 (61.7%) | 909 (25.3%) | 1999 (66.0%) | 4493 (37.2%) |
Gender | ||||||||||
Female, n (%) | 336 (38.7%) | 552 (99.5%) | 10 (55.6%) | 64 (58.2%) | 34 (100.0%) | 416 (100.0%) | 83 (55.7%) | 1854 (51.7%) | 1402 (46.3%) | 6302 (52.1%) |
Male, n (%) | 533 (61.3%) | 3 (0.5%) | 8 (44.4%) | 46 (41.8%) | 0 (0.0%) | 0 (0.0%) | 66 (44.3%) | 1735 (48.3%) | 1627 (53.7%) | 5791 (47.9%) |
Cancer Type | ||||||||||
Bile Duct, n (%) | 18 (2.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 18 (0.6%) | |||||
Breast, n (%) | 10 (1.2%) | 1 (5.6%) | 9 (26.5%) | 0 (0.0%) | 311 (10.3%) | |||||
Cervix, n (%) | 4 (0.5%) | 0 (0.0%) | 1 (2.9%) | 3 (2.0%) | 8 (0.3%) | |||||
Colorectum, n (%) | 103 (11.9%) | 2 (11.1%) | 1 (2.9%) | 2 (1.3%) | 604 (19.9%) | |||||
Endometrium, n (%) | 5 (0.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 5 (0.2%) | |||||
Gallbladder, n (%) | 22 (2.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 22 (0.7%) | |||||
Head and Neck, n (%) | 20 (2.3%) | 0 (0.0%) | 2 (5.9%) | 0 (0.0%) | 22 (0.7%) | |||||
Liver, n (%) | 62 (7.1%) | 0 (0.0%) | 8 (23.5%) | 0 (0.0%) | 314 (10.4%) | |||||
Lung, n (%) | 337 (38.8%) | 2 (11.1%) | 1 (2.9%) | 130 (87.2%) | 770 (25.4%) | |||||
Lymphoma, n (%) | 68 (7.8%) | 0 (0.0%) | 6 (17.6%) | 0 (0.0%) | 233 (7.7%) | |||||
Oesophagus, n (%) | 68 (7.8%) | 0 (0.0%) | 0 (0.0%) | 3 (2.0%) | 137 (4.5%) | |||||
Ovary, n (%) | 19 (2.2%) | 3 (16.7%) | 2 (5.9%) | 0 (0.0%) | 106 (3.5%) | |||||
Pancreas, n (%) | 25 (2.9%) | 3 (16.7%) | 0 (0.0%) | 0 (0.0%) | 153 (5.1%) | |||||
Stomach, n (%) | 103 (11.9%) | 2 (11.1%) | 4 (11.8%) | 1 (0.7%) | 259 (8.6%) | |||||
Others, n (%) | 5 (0.6%) | 5 (27.8%) | 0 (0.0%) | 10 (6.7%) | 67 (2.2%) | |||||
Stage | ||||||||||
I, n (%) | 34 (3.9%) | 0 (0.0%) | 0 (0.0%) | 33 (22.2%) | 423 (14.0%) | |||||
II, n (%) | 41 (4.7%) | 0 (0.0%) | 8 (23.5%) | 3 (2.0%) | 681 (22.5%) | |||||
III, n (%) | 97 (11.2%) | 1 (5.6%) | 9 (26.5%) | 10 (6.7%) | 557 (18.4%) | |||||
IV, n (%) | 403 (46.4%) | 2 (11.1%) | 14 (41.2%) | 27 (18.1%) | 580 (19.1%) | |||||
Unknown, n (%) | 233 (26.8%) | 14 (77.8%) | 3 (8.8%) | 76 (51.0%) | 788 (26.0%) | |||||
